<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03226951</url>
  </required_header>
  <id_info>
    <org_study_id>Protocol DME 2</org_study_id>
    <nct_id>NCT03226951</nct_id>
  </id_info>
  <brief_title>SDM Laser for Non Central Diabetic CSME</brief_title>
  <official_title>Sub Threshold Laser for Non Central Diabetic Clinical Significant Macular Edema</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Marashi Eye Clinic</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Marashi Eye Clinic</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Is to determine if SDM laser can reduce macular thickness in non central CSME and stop the
      progression of non central CSME to central CSME in compare to glycemic control
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      interventional randomised masked study will recruit patients have diabetes mellitus with non
      central CSME with good vision into two groups : 1st SDM laser with glycemic control 2nd SHAM
      laser with Glycemic control where BCVA will be recorded every month starting from baseline to
      24 weeks where OCT will be recorded every 8 weeks from baseline to 24 weeks
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">July 1, 2017</start_date>
  <completion_date type="Actual">February 1, 2018</completion_date>
  <primary_completion_date type="Actual">January 31, 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of eyes with reduced macular thickness</measure>
    <time_frame>24 weeks</time_frame>
    <description>Measurements of retinal thickness in the area of edema</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of eyes with reduced vision</measure>
    <time_frame>24 weeks</time_frame>
    <description>Best corrected visual acuity at the end of the study</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of eyes developing central macular edema</measure>
    <time_frame>24 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients achieved good glycemic control</measure>
    <time_frame>24 weeks</time_frame>
    <description>By measuring HbA1C every 12 weeks from baseline</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">8</enrollment>
  <condition>Non Central Diabetic Macular Edema</condition>
  <arm_group>
    <arm_group_label>Subtherhold 532 nm laser</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Applying 532nm subtherhold laser with 5% duty cycle using high density low intensity protocol at the area of non central clinical significant macular edema</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Subthreshold 532nm laser</intervention_name>
    <description>Subthershold 532nm laser</description>
    <arm_group_label>Subtherhold 532 nm laser</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with central diabetic macular edema Best corrected visual acuity is 20/30 or
             more

          -  Non central Macular thickness more than 250 microns

          -  Patients who are able to come for all follow-up

        Exclusion Criteria:

          -  Significant renal disease, defined as a history of chronic renal failure requiring
             dialysis or kidney transplant.

          -  Myocardial infarction, other acute cardiac event requiring hospitalization, stroke,
             transient ischemic attack, or treatment for acute congestive heart failure within 4
             months prior to randomization

          -  For women of child-bearing potential: pregnant or lactating or intending to become
             pregnant within the next 3 years.

          -  Macular edema is present that is considered to be related to ocular surgery such as
             cataract extraction

          -  Substantial cataract that, in the opinion of the investigator, is likely to be
             decreasing visual acuity by 3 lines or more

          -  History of major ocular surgery (including vitrectomy, scleral buckle, any intraocular
             surgery, etc.) within prior 4 months or anticipated within the next 6 months following
             randomization.

          -  Exam evidence of severe external ocular infection, including conjunctivitis,
             chalazion, or substantial blepharitis
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Marashi Eye Clinic</name>
      <address>
        <city>Aleppo</city>
        <zip>2241511</zip>
        <country>Syrian Arab Republic</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Syrian Arab Republic</country>
  </location_countries>
  <link>
    <url>http://medcraveonline.com/AOVS/AOVS-08-00291.pdf</url>
    <description>Non-central diabetic clinical significant macular edema treatment with 532nm sub threshold laser</description>
  </link>
  <results_reference>
    <citation>Marashi A. Non-central diabetic clinical significant macular edema treatment with 532nm sub threshold laser. Adv Ophthalmol Vis Syst. 2018;8(3):151â€’154. DOI: 10.15406/aovs.2018.08.0029</citation>
  </results_reference>
  <verification_date>October 2018</verification_date>
  <study_first_submitted>July 20, 2017</study_first_submitted>
  <study_first_submitted_qc>July 20, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">July 24, 2017</study_first_posted>
  <last_update_submitted>October 25, 2018</last_update_submitted>
  <last_update_submitted_qc>October 25, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">October 29, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Marashi Eye Clinic</investigator_affiliation>
    <investigator_full_name>Ameen Marashi</investigator_full_name>
    <investigator_title>Principle investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Macular Edema</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

